首页> 美国卫生研究院文献>Scientific Reports >Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer
【2h】

Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer

机译:血浆中循环的miR-497和miR-663b是潜在的新型膀胱癌生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

MicroRNAs (miRNAs), abundant and highly stable in the plasma, have been widely reported. This greatly pursued us to investigate whether plasma miRNAs could be considered as powerful biomarkers for diagnosing bladder cancer (BC). We performed a plasma miRNAs profile with the TaqMan Low Density Array, and a two-phase validation to detect the candidate miRNAs expression by quantitative PCR. The receiver operating characteristic curve (ROC) and the area under curve (AUC) were used to evaluate diagnostic accuracy. A total of eight plasma miRNAs abnormally expressed between BC patients and healthy controls in microarray analysis (i.e., elevated miRNAs for miR-505, miR-363 and miR-663b, and decreased for miR-99a, miR-194, miR-100, miR-497 and miR-1 in BC plasma). In further independent cohorts, miR-497 and miR-663b with significantly differential expression were confirmed. Moreover, the AUC, sensitivity and specificity were raised to 0.711 (95% CI = 0.641-0.780), 69.7% and 69.6%, respectively, when miR-497 and miR-663b were integrated. This is the first study systematically exploring the existence of specific plasma miRNAs as early diagnostic biomarkers for BC in Chinese population; and these findings supported that plasma miR-497 and miR-663b could be promising novel circulating biomarkers in clinical detection of BC.
机译:在血浆中丰富且高度稳定的MicroRNA(miRNA)已被广泛报道。这极大地促使我们研究了血浆miRNA是否可以被视为诊断膀胱癌(BC)的强大生物标记。我们使用TaqMan低密度阵列进行了血浆miRNA配置文件,并进行了两阶段验证,以通过定量PCR检测候选miRNA的表达。使用接收器工作特性曲线(ROC)和曲线下面积(AUC)评估诊断准确性。在微阵列分析中,BC患者和健康对照组之间总共共有八种血浆miRNA异常表达(即,miR-505,miR-363和miR-663b的miRNA升高,而miR-99a,miR-194,miR-100降低, BC血浆中的miR-497和miR-1)。在另外的独立队列中,证实了miR-497和miR-663b具有明显的差异表达。此外,将miR-497和miR-663b整合后,AUC,敏感性和特异性分别提高到0.711(95%CI = 0.641-0.780),69.7%和69.6%。这是第一项系统研究特定血浆miRNA作为中国人群BC早期诊断生物标志物的研究。这些发现支持血浆miR-497和miR-663b在BC临床检测中可能是有希望的新型循环生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号